Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
Oramed Pharmaceuticals Parties Intend For JV To Initiate Phase 3 Oral Insulin Trial In The U.S.; Oramed Will Be Entitled To Receive A 3% Royalty On Gross Revenues Of JV Generated From Oramed Related Assets
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.